started · updated
HITS secures 18.3 billion KRW in Series B funding for AI drug discovery
HITS, an artificial intelligence platform company specializing in drug discovery and biological data analysis, has secured 18.3 billion KRW in Series B funding. This brings the company's cumulative investment to 28.6 billion KRW.
Premier Partners led the round, with new participation from six institutions including Yuanta Investment & Securities, Samsung Securities, BSK Investment, TBT Partners, and IBK Venture Investment. Existing investors Korea Investment Partners, Capstone Partners, and Laplace Partners also provided follow-on funding.
HITS focuses on providing its AI research platform, ‘HyperLab’, to pharmaceutical companies and research institutions rather than developing its own drug pipelines. The company currently supplies HyperLab to major domestic pharmaceutical firms, the National Cancer Center, and cancer research institutes in the United States. It also collaborates with global life sciences firm Thermo Fisher Scientific.
The company plans to use the funds to execute a mid-to-long-term growth strategy through 2029. Key objectives include transitioning to ‘Agentic AI’ by the end of this year, enhancing ‘Science AI’ technologies by the first half of next year, and expanding its presence in the US and European markets by increasing local business development personnel and diversifying its delivery models.
Entities
HITS · Kim Woo-yeon · Lee Yong-hoon · Premier Partners · Thermo Fisher Scientific